25-hydroxyvitamin D deficiency, exacerbation frequency and human rhinovirus exacerbations in chronic obstructive pulmonary disease

BMC Pulmonary Medicine

Volumn 12, Issue , 2012, Pages

  Quint, Jennifer K ^a   Donaldson, Gavin C ^a   Wassef, Nancy ^b   Hurst, John R ^a   Thomas, Michael ^b   Wedzicha, Jadwiga A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; VITAMIN D RECEPTOR; 25-HYDROXYVITAMIN D; CALCITRIOL RECEPTOR; DRUG DERIVATIVE; VITAMIN D;

AGED; ARTICLE; BSMI GENE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; FEMALE; FOKI GENE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN RHINOVIRUS; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RECEPTOR GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHINOVIRUS INFECTION; SEASONAL VARIATION; SINGLE NUCLEOTIDE POLYMORPHISM; SUMMER; TAQIALPHA GENE; VIRUS DETECTION; VIRUS LOAD; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; WINTER; ACUTE DISEASE; BLOOD; FORCED EXPIRATORY VOLUME; GENETIC POLYMORPHISM; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHOTOPERIODICITY; PICORNAVIRUS INFECTION; RHINOVIRUS; SEASON;

ACUTE DISEASE; AGED; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MIDDLE AGED; PHOTOPERIOD; PICORNAVIRIDAE INFECTIONS; POLYMORPHISM, GENETIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, CALCITRIOL; RHINOVIRUS; SEASONS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84862538834     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-12-28     Document Type: Article

References (44)

1. Janssens W, Lehouck A, Carremans C, Bouillon R, Mathieu C, Decramer M. 25-hydroxyvitamin D beyond bones in chronic obstructive pulmonary disease: time to act. Am J Respir Crit Care Med 2009, 179(8):630-636. 10.1164/rccm.200810-1576PP, 19164701.
2. Mora JR, Iwata M, von Andrian UH. Vitmain effects on the immune system: vitamins A and D take centre stage. Nature Reviews Immunol 2008, 8:685-698.
3. Holik MF. 25-hydroxyvitamin D deficiency. N Eng J Med 2007, 357:266-281.
4. Waterhouse JC, Perez TH, Albert PJ. Reversing bacteria-induced 25-hydroxyvitamin D receptor dysfunction is key to autoimmune disease. Ann N Y Acad Sci 2009, 1173:757-765. 10.1111/j.1749-6632.2009.04637.x, 19758226.
5. Global Initiative for Chronic Obstructive Lung Disease Global Strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. (GOLD) 2006, , , http://www.goldcopd.org. Accessed 17th May 2009, Global Initiative for Chronic Obstructive Lung Disease.
6. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:1418-1422.
7. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003, 58:589-593. 10.1136/thorax.58.7.589, 1746751, 12832673.
8. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002, 57:847-852. 10.1136/thorax.57.10.847, 1746193, 12324669.
9. O'Brien JA, Ward AJ, Jones MKC, McMillan C, Lordan N. Utilization of health care services by patients with chronic obstructive pulmonary disease. Respir Med 2003, 97(1):S53-S58.
10. Groenewegen KH, Schols AMWJ, Wouters EFM. Mortality and mortality related factors after hospitalisation for acute exacerbation of COPD. Chest 2003, 124:459-467. 10.1378/chest.124.2.459, 12907529.
11. Seemungal TAR, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:1618-1623.
12. Wilkinson TMA, Hurst JR, Perera WR, et al. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest 2006, 129:317-324. 10.1378/chest.129.2.317, 16478847.
13. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363(12):1128-1138. 10.1056/NEJMoa0909883, 20843247.
14. Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 171:446-452.
15. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:358-364.
16. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PMA. Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease: Results from the TORCH Study. Am J Respir Crit Care Med 2008, 178:332-338. 10.1164/rccm.200712-1869OC, 18511702.
17. Bhowmik A, Seemungal TAR, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000, 55:114-120. 10.1136/thorax.55.2.114, 1745686, 10639527.
18. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005, 57:137-141.
19. Eccles R. An Explanation for the Seasonality of Acute Upper Respiratory Tract Viral Infections. Acta Otolaryngol 2002, 122(2):183-191. 10.1080/00016480252814207, 11936911.
20. Hope-Simpson RE. The role of season in the epidemiology of influenza. J Hyg (Lond) 1981, 86(1):35-47.
21. Leow L, Simpson T, Cursons R, Karalus N, Hancox RJ. Vitamin D, innate immunity and outcomes in community acquired pneumonia. Respirology 2011, 16(4)):611-616.
22. Janssens W, Bouillon R, Claes B, Carremans C, Lehouck A, Buysschaert I, Coolen J, Mathieu C, Decramer M, Lambrechts D. 25-hydroxyvitamin D deficiency is highly prevalent in COPD and correlates with variants in the 25-hydroxyvitamin D-binding gene. Thorax 2010, 65(3):215-220. 10.1136/thx.2009.120659, 19996341.
23. Forli L, Bjortuft O, Boe J. Vitamin D status in relation to nutritional depletion and muscle function in patients with advanced pulmonary disease. Exp Lung Res 2009 Aug, 35(6):524-538.
24. Schellenberg D, Pare PD, Weir TD, Spinelli JJ, Walker BAM, Sandford AJ. 25-hydroxyvitamin D Binding Protein Variants and the Risk of COPD. Am J Respir Crit Care Med 1998, 157:957-961.
25. Lauridsen AL, Vestergaard P, et al. Plasma concentrations of 25-Hydroxy-25-hydroxyvitamin D and 1,25-Dihydroxy-25-hydroxyvitamin D are Related to the Phenotype of Gc (25-hydroxyvitamin D-Binding Protein): A Cross-sectional Study on 595 Early Postmenopausal Women. Calcified Tissue International, Springer New York 2005, 77(1):15-22.
26. Taes YEC, Goemaere S, Huang G, Van Pottelbergh I, De Bacquer D, Verhasselt B, Van den Broeke C, Delanghe JR, Kaufman JM. 25-hydroxyvitamin D binding protein, bone status and body composition in community-dwelling elderly men. Bone 2006, 38(5):701-707. 10.1016/j.bone.2005.10.006, 16309986.
27. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of 25-hydroxyvitamin D receptor polymorphisms. Gene 2004, 338(2):143-156. 10.1016/j.gene.2004.05.014, 15315818.
28. Quint JK, Donaldson GC, Goldring JJ, Baghai-Ravary R, Hurst JR, Wedzicha JA. Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest 2010 Apr, 137(4):812-822.
29. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006, 61(9):772-778. 10.1136/thx.2006.060145, 2117100, 16738033.
30. Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, Meunier PJ. Prevalence of 25-hydroxyvitamin D insufficiency in an adult normal population. Osteoporos Int 1997, 7(5):439-443. 10.1007/s001980050030, 9425501.
31. Brehm JM, Celedón JC, Soto-Quiros ME, Avila L, Hunninghake GM, Forno E, Laskey D, Sylvia JS, Hollis BW, Weiss ST, Litonjua AA. Serum 25-hydroxyvitamin D levels and markers of severity of childhood asthma in Costa Rica. Am J Respir Crit Care Med 2009, 179(9):765-771. 10.1164/rccm.200808-1361OC, 2675563, 19179486.
32. Kunisaki KM, Niewoehner DE, Connett JE. COPD Clinical Research Network, Vitamin D levels and risk of acute exacerbations of chronic obstructive pulmonary disease: a prospective cohort study. Am J Respir Crit Care Med 2012 Feb 1, 185(3):286-290.
33. Lehouck A, Mathieu C, Carremans C, Baeke F, Verhaegen J, Van Eldere J, Decallonne B, Bouillon R, Decramer M, Janssens W. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2012 Jan 17, 156(2):105-114.
34. Ginde AA, Mansbach JM, Camargo CA. Association between serum 25-hydroxy25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009, 169(4):384-390. 10.1001/archinternmed.2008.560, 19237723.
35. Laaksi I, Ruohola JP, Tuohimaa P, Auvinen A, Haataja R, Pihlajamäki H, Ylikomi T. An association of serum 25-hydroxyvitamin D concentrations < 40 nmol/L with acute respiratory tract infection in young Finnish men. Am J Clin Nutr 2007, 86(3):714-717.
36. Martineau AR, Wilkinson RJ, Wilkinson KA, Newton SM, Kampmann B, Hall BM, Packe GE, Davidson RN, Eldridge SM, Maunsell ZJ, Rainbow SJ, Berry JL, Griffiths CJ. A Single Dose of 25-hydroxyvitamin D Enhances Immunity to Mycobacteria Am. J. Respir. Crit. Care Med 2007, 176:208-213.
37. Wejse C, Gomes VF, Rabna P, Gustafson P, Aaby P, Lisse IM, Andersen PL, Glerup H, Sodemann M. 25-hydroxyvitamin D as Supplementary Treatment for Tuberculosis: A Double-blind, Randomized, Placebo-controlled Trial. Am J Respir Crit Care Med 2009, 179:843-850. 10.1164/rccm.200804-567OC, 19179490.
38. Roth DE, Jones AB, Prosser C, Robinson JL, Vohra S. 25-hydroxyvitamin D receptor polymorphisms and the risk of acute lower respiratory tract infection in early childhood. J Infect Dis 2008, 197(5):676-680. 10.1086/527488, 18266602.
39. Sadeghi K, Wessner B, Laggner U, et al. 25-hydroxyvitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen associated molecular patterns. Eur J Immunol 2006, 36:361-370. 10.1002/eji.200425995, 16402404.
40. Bhalla AK, Amento EP, Krane SM. Differential effects of 1,25 dihydroxy25-hydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: inhibition of interleukin 2 and augmentation of interleukin1 production. Cell Immunol 1986, 98:311-322. 10.1016/0008-8749(86)90291-1, 3489547.
41. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a 25-hydroxyvitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773. 10.1126/science.1123933, 16497887.
42. Norman AW, Bouillon R, Whiting SJ, Vieth R, Lips P. 13th Workshop consensus for 25-hydroxyvitamin D nutritional guidelines The Journal of Steroid Biochemistry and. Mol Biol 2007, 103(3-5):204-205.
43. Quint JK, Donaldson GC, Hurst JR, Goldring JJ, Seemungal TR, Wedzicha JA. Predictive accuracy of patient reported exacerbation frequency in chronic obstructive pulmonary disease. Eur Respir J 2011, 37(3):501-507. 10.1183/09031936.00035909, 20650988.
44. Bhowmik A, Seemungal TAR, Sapsford RJ, Devalia JL, Wedzicha JA. Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease. Thorax 1998, 53:953-956. 10.1136/thx.53.11.953, 1745116, 10193394.